• An experienced Corporate Director and CEO: Doug has chaired the board of directors of a NASDAQ-listed company and as a CEO for the past 12 years has built and turned-around three pharmaceutical companies.
• During Doug’s 30 years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 15 corporate acquisitions across three continents and has raised $4 billion of both public and private capital.
• Led the turnaround of Norwich Pharmaceuticals alongside investors and became the Founding CEO of parent company, Alvogen Group. During his 5.5 year tenure as CEO, Alvogen grew from inception to $450 million in revenues across 35 countries.
• In early 2014, Doug led the recapitalization of NASDAQ-listed Pernix Therapeutics, raising $65 million. Within the first year of taking the helm as Chairman and CEO, Doug rebuilt the management team and board of directors, combined several operating locations, and grew the company’s enterprise value from $80 million to around $800 million. Under Doug’s leadership, Pernix raised $465 million of capital.
• From November 2017 to July 2020, Doug was a Director and CEO of Tedor Pharma, a family-owned contract manufacturing business. Doug’s efforts to turnaround the business resulted in 60% revenue growth in 2019, leading to Tedor being recognized as one of America’s fastest-growing companies, making it to the 2020 Inc 5000 list.
• Former Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents, between 2004 and 2008, including a high-profile public hostile takeover attempt in Central Eastern Europe. Over this period, Doug raised approximately $3 billion of capital and managed lending syndicates including 25+ banks, to fund the company’s growth. Actavis was sold to Watson Pharmaceuticals in 2012 for EUR4.25 billion.
• Doug holds a bachelor’s degree in Microbial and Molecular Biology from the University of East Anglia in the U.K. and was recognized as Entrepreneur of the Year by Ernst and Young, in 2012. Doug is an enthusiastic traveler, having traveled to over 45 countries, is an avid reader and enjoys cooking and boating.

• Former Chief Quality, Patient Safety, HSE & Risk Officer at UCB, Inc leading a team of 1500+ colleagues in 54 countries.
• Former President at UCB, Inc. leading US commercial operations through the restructuring into CNS and Immunology Business Units with annualized 27% P&L growth ($2.2B in revenue).
• Various Director level research, regulatory and managerial roles at Eli Lilly from 1997 to 2006.

• Former Lead Compliance Program Designer of the non-medical cannabis compliance program at a major Canadian retailer.
• ISO 19600 Certified Senior Lead Compliance Manager.
• PROSCI Certified Change Management Practitioner.
• Vast experience and knowledge in the design and operation of foundational programs (regulatory compliance, operational) and organizational design & strategy implementation and execution.

• Qualified psychiatrist and pharmaceutical physician with over 20 years of clinical and drug development experience.
• Successfully progressed numerous candidate drugs through preclinical development and early phase clinical trials to proof-of-concept studies
• Experienced in leading global teams overseeing development of novel medications across a range of psychiatric indications including treatment resistant depression, narcolepsy, anxiety, schizophrenia, bipolar disorder and substance use disorders.

• Lead NCE inventor of multiple successfully partnered drug discovery and development programs.
• Technology developer of the proprietary formulations for CNS drugs.
• Seasoned medicinal chemist, drug delivery expert and founder of multiple biotech companies.

• Co-Founder and Managing Director of Trinity Venture Partners Inc, a Canadian boutique merchant bank.
• Co-Founder of multiple start-ups across various sectors.
• 10+ years experience in medical device manufacturing and regulatory frameworks.
• Successfully raised over $100M for various start-ups.

• 15+ years experience creating efficient scalable operations financial reporting, IFRS; regulatory reporting OSFI.
• Former Ontario Securities Commission contracted Director of Finance.
• Former Scotiabank senior manager of enterprise functions.
• Former CFO of Global Maxfin Investments Inc.
• Former CIBC small business lending controller. Authority over assets of $31B for external reporting on a monthly and quarterly basis.

Gabe Fahel brings extensive experience in corporate commercial matters and government relations with more than 20 years as counsel with law firms, private and public companies, and government and non-governmental organizations. Gabe has a broad range of experience managing multijurisdictional and multidisciplinary teams in fast-paced and politically charged environments. He has been engaged in complex and intractable areas of international law and advanced novel legal issues of law before every level of court in Canada, including the Supreme Court of Canada. Gabe is also a founding board member of Psychedelics Canada. 

• Passionate about developing novel treatment protocols in CNS therapeutics to advance unmet medical needs. Translate business strategy into optimal solutions by building and partnering with premier providers
• Well networked in developing and nurturing strong Key Opinion Leader (KOL)relationships in Phase I – IV Trials.
• Extensive background in various therapeutic areas (TAs) with a special emphasis on CNS indications. Experience includes, Alzheimer’s, mild cognitive impairment, schizophrenia (CIAS, negative, and positive symptoms), bipolar disorder (mania and depressive state) and MDD.
• Significant experience with the unique challenges in phase I (first in human, SAD, MAD, complex cohort management) and orphan indications (Friederichs’s ataxia, behavioral variant FTD, FTD with Progranulin Mutation).

• Neuroscientist and drug discoverer with a proven record of progressing novel molecular entities into clinical trials.
• Over 20 years of experience in the pharmaceutical industry with scientific leadership and managerial roles in Research & Development at Schering Plough, Sanofi, and Merck.
• Contributed to the clinical testing of several compounds with one of the compounds (rolapitant) approved and marketed as VARUBI for the treatment of chemotherapy-induced nausea and vomiting.
• Managed the out-sourcing of in-vivo studies to Contract Research Organizations (CROs) for Merck’s major therapy areas.
• Published research in over 130 journal articles and abstracts.

• Ph.D. in Organic Chemistry with detailed knowledge of pharmaceutical development.
• Direct detailed experience in synthetic organic, analytical and formulation development chemistry with excellent trouble shooting ability.
• Experience in outsourcing / technology transfer management to domestic and international CROs to support clinical and preclinical projects for drug substance and drug product.

• Dr. Rahman has over 25 years of experience in the pharmaceutical industry, primarily in Pharmacovigilance, but also in Clinical Development, Pharmacoeconomics, Medical Affairs, Manufacturing, and Regulatory Affairs.
• Previously, Dr. Rahman served in leadership positions at global healthcare companies, including Organon and Otsuka Pharmaceuticals, where he played an integral role in leading the pharmacovigilance strategy and prioritizing patient safety.
• Prior to joining the pharmaceutical industry, Dr. Rahman worked in academia as an Assistant Professor at the Case Western Reserve University School of Medicine in Ohio, and in public health, as the Medical Director of a Community Health Center in New York.
• Dr. Rahman currently serves as the President of both the American College of Preventive Medicine and the Guyanese Diaspora Charity. In addition, he is an Adjunct Associate Professor at both Columbia University & the University of Guyana. He is a trained Family Physician who is board-certified in Public Health & General Preventive Medicine.

• Dr. Atul R. Mahableshwarkar is a Board Certified Psychiatrist and a Distinguished Life Fellow of the American Psychiatric Association. He has had multiple leadership roles in Academia, Clinical practice, the Scientific Community and the Pharmaceutical Industry with a track record for innovative problem solving and delivering successful outcomes.
• Dr. Mahableshwarkar has Lead development programs in Anxiety disorders, Alzheimer’s, Bipolar disorder, Cervical Dystonia, Childhood Onset Fluency Disorders, Frequently Relapsing Bipolar disorder, Major depression, Social Anxiety Disorder, Parkinson’s disease, Plantar Fasciitis, Schizophrenia, Tourette’s Syndrome, Upper limb spasticity leading to successful filing of INDs, NDAs, and an sNDA.
• He’s had leadership roles as CMO and SVP/VP for clinical Development in growth stage startup and small Biotech/Pharma responsible for pipeline and working with C-Suite on strategic company growth, presentations to and interactions with investors, company Boards and external audiences including regulators such as the FDA, EMA, PMDA etc. Significant input in due diligence for Companies, platforms and molecules for both internal and external (Venture Capital) organizations.
• Dr. Mahableshwarkar has over 180 scientific publications/posters/oral presentations and is a founding Member of two Scientific societies and serves on the Scientific, Program, Leadership and Executive Committees of various Scientific Societies.

• Established Global Program/Asset Strategy and Clinical Development Team Leader with 25+ years of experience in pharma/biotech management and New Drug Development for serious medical conditions in multiple therapeutic areas (psychiatry/neurology, rare diseases, immunology/oncology, GI/GU, and others).
• Highly experienced in all phases of new drug development (pre-candidate and Phase 1 – 4) of diverse treatment modalities (small molecules, antibodies, oligonucleotides, and gene therapies) and cross-functional program leadership within highly matrixed, multinational corporations.
• Has led or supported the global development and approval of psychiatric products for schizophrenia, bipolar disorder, insomnia, and depression and neurological products for spinal muscular atrophy.

• 25 years in the pharmaceutical industry as a project manager and CMC consultant, specialising in analytical and formulation development
• Co-founder of biotech company Small Pharma, which was acquired by Cybin in 2023
• Author or reviewer of the quality sections for numerous regulatory submissions
• Responsible for the development of numerous drug product formulations
• Advised multiple large pharma projects on CMC drug development

• Highly skilled executive with 20+ years of management experience in pharmaceutical development operations, early stage, and late-stage development.
• Strategic professional with proven expertise in CMC ensures that pharmaceutical and biopharmaceutical drug products are consistently effective, safe and high quality.
• Experienced in laboratory research, scale up, and technology transfer to ensure optimal product quality of drugs from R&D to late-stage approval.
• Strong knowledge of establishing strategies for Process Control, Process Qualification and Process Performance Qualification in order to produce coast saving processes and manufacturing of complex molecules from lab to commercial scale.
• Post-doctoral research with Nobel Laureate Prof H.C.Brown, Purdue University.

Dr. Alex Kelman is the Head of Therapies at Cybin and an Attending Psychologist and Assistant Clinical Professor at the University of California, Los Angeles (UCLA). Prior to his current role at Cybin, Dr. Kelman was the Director of Training of the UCLA Prevention Center of Excellence in the Semel Institute for Neuroscience and Human Behavior. Dr. Kelman has published manuscripts on behavioral health equity, mindfulness, compassion, trauma-informed systems of care, and novel methods of service delivery and has done extensive community-based and academic teaching in these areas.

• Marcelo Gutierrez graduated with a PhD in Bioengineering and Therapeutic Sciences from the University of California, San Francisco. In 1994, he started his career in Clinical Pharmacology at Forest Research Institute in New York City where he was responsible for the clinical pharmacology program of all drugs in the CNS division, successfully bringing four drugs through NDA submission and approval including Celexa, Lexapro and Namenda.
• He joined Actelion Pharmaceuticals in Allschwil, Switzerland in 2008 as Deputy Head, Clinical Pharmacology, responsible for the CP programs of several drugs in various therapeutic areas including anti-infectives, cardiovascular and allergy.
• In 2012, he joined Novartis in Basel, Switzerland as Head of Global Scientific Development, responsible for reviewing the portfolio of NIBR drugs prior to transfer to Novartis Pharma Division. He also developed clinical pharmacology courses for non-CPs and helped build translational medicine capability in emerging countries (with a focus on Africa).
• Since 2021 and before joining Cybin, Marcelo held the position of Head, Clinical Pharmacology, DMPK and Bioanalytics at Amylyx Pharmaceuticals, developing medicines for ALS and other orphan diseases. In his spare time, he enjoys cooking (mainly Asian cuisine), tennis, volleyball and traveling.

• Former Controller at Knight Therapeutics Inc.
• Former auditor at Ernst & Young
• Holds a Bachelor of Commerce degree and a Graduate Diploma in Public Accountancy from McGill University and is a Chartered Professional Accountant

• 25 years of experience working with leading corporations in administrative support roles to senior leadership.
• 10+ years of law firm and in-house corporate law clerk experience working in rapidly evolving tech-based industries.
• Oversight of national and international legal and corporate matters with specialty in corporate restructuring, tax reorganizations, acquisitions, and public company listings and filings.
• Responsible for maintaining corporate records and database.

• PhD and postdoctoral training at Imperial College London
• 10 years in the pharmaceutical industry specialising in clinical development
• Lead for successful proof-of-concept study with DMT in major depression
• Author of many scientific publications, posters and presentations
• Responsible for the clinical development of psychedelic compounds since 2019

• Responsible for a wide range of legal matters including contracts, intellectual property, US employment agreements, and contracts for R&D, Pre-clinical, Clinical, Regulatory, and Business Development teams.
• Over 20 years of diverse experience including general counsel, IP attorney, commercial roles, and laboratory researcher
• Registered Patent Attorney, USPTO, Licensed to Practice Law in FL, DC, and MA
• Regulatory Affairs Certificate for Pharmaceutical and Medical Devices, RAPS; Copyright Law Certificate, Harvard University
• JD, MBA, MS (Molecular Genetics, Pharmacology), University of Florida; BS (Genetics, Chemistry), University of Georgia

• Responsible for a wide range of legal matters including intellectual property, contracts for R&D and Clinical Trials, GDPR, and UK employment matters.
• Over 20 years of experience in the pharmaceutical and healthcare industries, including as an in-house patent attorney with major pharmaceutical companies.
• Chartered (UK) Patent Attorney, European Patent Attorney, Solicitor (England and Wales).

• IT professional with 20 years experience
• A passion for technology & data insights
• Driving innovative, cost effective, secure IT solutions